Sinovac Biotech CoronaVac COVID-19 vaccine candidate succeeds in phase 1/2 trial
Sinovac Biotech said that the phase 1/2 clinical trial for its coronavirus vaccine candidate CoronaVac has delivered positive preliminary results by showing favorable immunogenicity and safety profiles.
According to the Chinese biopharma company, the phase 1/2 clinical trials are randomized, double-blind and placebo-controlled studies featuring 743 healthy volunteers, aged between 18 and 59 years.
Of the enrolled patients, 143 volunteers are in phase I and the remaining 600 volunteers are in phase II trial.
Sinovac Biotech said that there have been no severe adverse event noted in either the phase 1 or phase 2 clinical trials. The phase 2 clinical trial results show that the CoronaVac vaccine induces neutralizing antibodies two weeks after the vaccination with a 0,14 day schedule.
The Chinese biopharma company said that the neutralizing antibody seroconversion rate is more than 90%, which proves that the COVID-19 vaccine candidate can trigger a positive immune response.
Sinovac Biotech said that it is looking to submit a phase 2 clinical trial report and a phase 3 clinical study protocol to China’s National Medical Products Administration (NMPA) in the near future and start filing application of phase 3 COVID-19 clinical trials outside of China.
Earlier this month, Sinovac announced a collaboration with Instituto Butantan in Brazil to prepare and carry out a phase 3 coronavirus clinical study. The Chinese biopharma company anticipates sharing the full data of its COVID-19 clinical trials with the public via academic publications.
Weidong Yin – Chairman, President and CEO of Sinovac said: “Our phase I/II study shows CoronaVac is safe and can induce immune response. Concluding our phase I/II clinical studies with these encouraging results is another significant milestone we have achieved in the fight against COVID-19. We have started to invest in building a manufacturing facility so that we can maximize the number of doses available to protect people from COVID-19.
“Like with our other vaccines, we are committed to developing CoronaVac for global use as part of our mission of supplying vaccines to eliminate human diseases.”
Related posts
Business News Today